|
Novartis hands Ophthotech a $1B deal for heavyweight wet AMD contender
FierceBiotech Novartis ($NVS) has scooped up the ex-U.S. rights to Ophthotech’s Fovista–its late-stage therapy for wet age-related macular degeneration that hopes to one day rival heavyweight franchises controlled by Roche ($RHHBY) and Regeneron ($REGN)–in a … Ophthotech Corp (OPHT), Novartis Enter ex-US Licensing Agreement for Wet …StreetInsider.com (subscription) Ophthotech may get over $1 billion from eye drug deal with NovartisReuters Novartis announces exclusive agreement to extend leadership in ophthalmology …MarketWatch The Wall Street Transcript –Xconomy all 22 news articles |
Source: Wet Macular Degeneration News From Google News
Zennie Abraham | Zennie Abraham or “Zennie62” is the founder of Zennie62Media which consists of zennie62blog.com and a multimedia blog news aggregator and video network, and 78-blog network, with social media and content development services and consulting. Zennie is a pioneer video blogger, YouTube Partner, social media practitioner, game developer, and pundit. Note: news aggregator content does not reflect the personal views of Mr. Abraham.